

## DAFTAR PUSTAKA

- Alavi-Moghadam M (2014). *Incidence of imipenem-resistant Acinetobacter baumannii in a general intensive care unit (ICU)*.
- Almasaudi SB (2018). *Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features*. Saudi J Biol Sci, 25(3):586–596.
- Almoghribi Y, Daghistani H, Niyazi H, Niyazi H, AbdulMajed H, Juma N *et al.* (2024). Epidemiological and Clinical Insights into *Acinetobacter baumannii*: A Six-Year Study on Age, Antibiotics, and Specimens. IJGM, Volume 17:5715–5725. doi:10.2147/IJGM.S489514.
- Al-Obeid S, Jabri L, Al-Agamy M, Al-Omari A, Shibl A (2015). Epidemiology of extensive drug resistant *acinetobacter baumannii* (XDRAB) at security forces hospital (SFH) in Kingdom of Saudi Arabia (KSA). JOC, 27(3):156–162.
- Alotaibi T, Abuhaimed A, Alshahrani M, Albdelhady A, Almubarak Y, Almasari O (2021). Prevalence of multidrug-resistant *Acinetobacter baumannii* in a critical care setting: A tertiary teaching hospital experience. SAGE Open Med, 9:2–3.
- Al-Shamiri MM, Zhang S, Mi P, Liu Y, Xun M, Yang E *et al.* (2021). Phenotypic and genotypic characteristics of *Acinetobacter baumannii* enrolled in the relationship among antibiotic resistance, biofilm formation and motility. MicPath, 155:2.
- Anon (2013). *Riset Kesehatan Dasar 2013*.
- Armstrong T, Fenn SJ, Hardie KR (2021). JMM Profile: Carbapenems: a broad-spectrum antibiotic. JMM, 70(12).
- Asif M, Alvi IA, Ur Rehman S (2018). Insight into *Acinetobacter baumannii*: Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist, 11:1249–1260.
- Aydın M, Azak E, Bilgin H, Menekse S, Asan A, Mert HTE *et al.* (2021). Changes in antimicrobial resistance and outcomes of health care–associated infections. EJCMID, 40(8):1737–1742.
- Ayobami O, Willrich N, Harder T, Okeke IN, Eckmanns T, Markwart R (2019). The incidence and prevalence of hospital-acquired (carbapenem-resistant) *Acinetobacter baumannii* in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. Emerg Microbes Infect, 8(1):1747–1759.
- Barreto ML, Teixeira MG, Carmo EH (2006). Infectious diseases epidemiology. JECH, 60(3):192–195.
- Bergogne-Bé E, Zin RÉ, Towner KJ (1996). *Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features*. CMR, 9(2):148–165. doi:10.1128/CMR.9.2.148.
- Blumer JL (1997). Antimicrobial Agents Meropenem: evaluation of a new generation carbapenem. IJAA, 8:73–92.
- Cakirlar FK, Ciftci IH, Gonullu N (2015). OXA-type Carbapenemases and Susceptibility of Colistin and Tigecycline Among Carbapenem-Resistant *Acinetobacter Baumannii* Isolates from Patients with Bacteremia in Turkey. CLIN LAB, 61(7):741–747. doi:10.7754/CLIN.LAB.2014.141116.



- Castanheira M, Mendes RE, Gales AC (2023). Global Epidemiology and Mechanisms of Resistance of *Acinetobacter baumannii*-calcoaceticus Complex. *CID*, 76(2):S166–S178.
- Chen W, Zhang D, Lian W, Wang X, Du W, Zhang Z *et al.* (2020). Imipenem population pharmacokinetics: Therapeutic drug monitoring data collected in critically ill patients with or without extracorporeal membrane oxygenation. *AAC*, 64(6).
- Clark RB (1996). Brief reports Imipenem resistance among *Acinetobacter baumannii*: association with reduced expression of a 33-36 kDa outer membrane protein. *JAA*, 38:245–251. (<https://academic.oup.com/jac/article/38/2/245/794835>).
- Collins AS (2008). *Preventing Health Care–Associated Infections*. (<https://www.ncbi.nlm.nih.gov/books/NBK2683/>, accessed 8 July 2023).
- D’Atri F, Arthur J, Blix HS, Hicks LA, Plachouras D, Monnet DL *et al.* (2019). Targets for the reduction of antibiotic use in humans in the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) partner countries. *ES*, 24(28).
- Dexter C, Murray GL, Paulsen IT, Peleg AY (2015). Community-acquired *Acinetobacter baumannii*: clinical characteristics, epidemiology and pathogenesis. *Expert Rev Anti Infect Ther*, 13(5):567–573. doi:10.1586/14787210.2015.1025055.
- Domingue JC, Drewes JL, Merlo CA, Housseau F, Sears CL (2020). Host responses to mucosal biofilms in the lung and gut. *Mucosal Immunol*, 13(3):413–422.
- Eze EC, Chenia HY, El Zowalaty ME (2018). *Acinetobacter baumannii* biofilms: Effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. *IDR*, 11:2277–2299.
- Ezeddin MO, Nasrul E, Alia E (2022). Prevalensi dan Pola Sensitivitas Antibiotik *Acinetobacter baumannii* di RSUP. Dr. M. Djamil Padang. *MKA*, 45(1):12.
- Feng DY, Zhou JX, Li X, Wu W Bin, Zhou YQ, Zhang TT (2022). Differentiation Between *Acinetobacter Baumannii* Colonization and Infection and the Clinical Outcome Prediction by Infection in Lower Respiratory Tract. *IDR*, 15:5401–5409.
- Friedman ND, Temkin E, Carmeli Y (2015). The negative impact of antibiotic resistance. *CMI*, 22:416–422. doi:10.1016/j.cmi.2015.12.002.
- Gajic I, Kabic J, Kekic D, Jovicevic M, Milenkovic M, Mitic Culafic D *et al.* (2022). Antimicrobial Susceptibility Testing: A Comprehensive Review of Currently Used Methods. *Antibiotics*, 11(4).
- Gao L, Lyu Y, Li Y (2017). Trends in drug resistance of *Acinetobacter baumannii* over a 10-year period: Nationwide data from the China surveillance of antimicrobial resistance program. *CMJ*, 130(6):659–664.
- Gaynes R, Edwards JR (2005). Overview of Nosocomial Infections Caused by Gram-Negative Bacilli Downloaded from. *CID*, 2:848. (<http://cid.oxfordjournals.org/>).
- Gesundheit B (2023). *DART 2030 – Deutsche Antibiotika-Resistenzstrategie*. Berlin.
- Güven T, Yilmaz G, Güner HR, Kaya Kalem A, Eser F, Taşyaran MA (2014). Increasing resistance of nosocomial *Acinetobacter baumannii*: Are we going to be defeated? *TJMS*, 44(1):73–78.



- Hafiz TA, Alghamdi SS, Mubarak MA, Alghamdi SSM, Alothaybi A, Aldawood E *et al.* (2023). A two-year retrospective study of multidrug-resistant *Acinetobacter baumannii* respiratory infections in critically ill patients: Clinical and microbiological findings. *JIPH*, 16(3):313–319.
- Hamidian M, Nigro SJ (2019). Emergence, molecular mechanisms and global spread of carbapenem-resistant *Acinetobacter baumannii*. *Microb Genom*, 5(10).
- Howard A, O'Donoghue M, Feeney A, Sleator RD (2012). *Acinetobacter baumannii* An emerging opportunistic pathogen. *Virulence*, 3(3):5.
- Ibrahim S, Al-Saryi N, Israa , Al-Kadmy MS, Sarah , Aziz N (2021). Multidrug-resistant *Acinetobacter baumannii* as an emerging concern in hospitals. *Mol Biol Rep*, 48:6987–6998. doi:10.1007/s11033-021-06690-6.
- Indah D, Pratiwi N, Danesihdewi A (2020). The prevalence of carbapenem-resistant *Acinetobacter baumannii* in Ulin General Hospital Banjarmasin. *EurAsia J Biosci*:7787–7792.
- Jeon CH, Kim SH, Kim HT, Park KJ, Wi YM (2024). Ineffectiveness of colistin monotherapy in treating carbapenem-resistant *Acinetobacter baumannii* Pneumonia: A retrospective single-center cohort study. *JIPH*, 17(5):774–779.
- Jiménez-Guerra G, Heras-Cañas V, Gutiérrez-Soto M, Aznarte-Padial M del P, Expósito-Ruiz M, Navarro-Marí JM *et al.* (2018). Urinary tract infection by *Acinetobacter baumannii* and *Pseudomonas aeruginosa*: Evolution of antimicrobial resistance and therapeutic alternatives. *JMM*, 67(6):790–797. doi:10.1099/JMM.0.000742/CITE/REFWORKS.
- Kim UJ, Kim HK, An JH, Cho SK, Park K-H, Jang H-C (2014). Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant *Acinetobacter* infections . *CMJ*, 50(2):37.
- Lee YL, Ko WC, Hsueh PR (2023). Geographic patterns of *Acinetobacter baumannii* and carbapenem resistance in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2019. *IJID*, 127:48–55.
- Lestari YE, Andrajati R, Nusatia ACM (2020). Hubungan Kejadian Infeksi Carbapenem Resistant *Acinetobacter baumannii* dengan Penggunaan Antibiotika Golongan Karbapenem pada Pasien di Rumah Sakit St. Carolus. *IJCP*, 9(3):189.
- Li S, Duan X, Peng Y, Rui Y (2019). Molecular characteristics of carbapenem-resistant *Acinetobacter* spp. From clinical infection samples and fecal survey samples in Southern China. *BMC Infect Dis*, 19(1):2.
- Liou BH, Lee YT, Kuo SC, Liu PY, Fung CP (2015). Efficacy of tigecycline for secondary *Acinetobacter* bacteremia and factors associated with treatment failure. *AAC*, 59(6):3637–3640. doi:10.1128/AAC.04987-14.
- Lob SH, Hoban DJ, Sahm DF, Badal RE (2016). Regional differences and trends in antimicrobial susceptibility of *Acinetobacter baumannii*. *IJAA*, 47(4):317–323.
- Ma C, McClean S (2021). *Mapping Global Prevalence of the Opportunist Acinetobacter baumannii and Recent Vaccine Development to Tackle It Supplementary Materials*.
- Mahon CR, Lehman DC (2019). *Textbook of Diagnostic Microbiology, Sixth Edition*, 6th ed. Missouri (<http://evolve.elsevier.com/Mahon/microbiology/YOU'VEJUSTPURCHASED>).



- Mayasari E, Siregar C (2015). Prevalence of *Acinetobacter baumannii* isolated from clinical specimens in Adam Malik Hospital. *MKA*, 37(1):4.
- Meletis G (2016). Carbapenem resistance: overview of the problem and future perspectives. *TAID*, 3(1):15–21.
- Mortazavi SM, Farshadzadeh Z, Janabadi S, Musavi M, Shahi F, Moradi M *et al.* (2020). Evaluating the frequency of carbapenem and aminoglycoside resistance genes among clinical isolates of *Acinetobacter baumannii* from Ahvaz, south-west Iran. *JNMNI*, 38.
- Mussi MA, Limansky AS, Viale AM (2005). Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of *Acinetobacter baumannii*: Natural insertional inactivation of a gene encoding a member of a novel family of  $\beta$ -barrel outer membrane proteins. *AAC*, 49(4):1432–1440.
- Mussi MA, Relling VM, Limansky AS, Viale AM (2007). CarO, an *Acinetobacter baumannii* outer membrane protein involved in carbapenem resistance, is essential for l-ornithine uptake. *FEBSLET*, 581(29):5573–5578.
- Nguyen M, Joshi SG (2021). Carbapenem resistance in *Acinetobacter baumannii*, and their importance in hospital-acquired infections: a scientific review. *JAM*, 131(6):2715–2738.
- Nikibakhsh M, Firoozeh F, Badmasti F, Kabir K, Zibaei M (2021). Molecular study of metallo- $\beta$ -lactamases and integrons in *Acinetobacter baumannii* isolates from burn patients. *BMC Infect Dis*, 21(1).
- Nutman A, Temkin E, Wullfhart L, Schechner V, Schwaber MJ, Carmeli Y (2023). *Acinetobacter baumannii* Bloodstream Infections: A Nationwide Study in Israel. *Microorganisms*, 11(9):2178. doi:10.3390/MICROORGANISMS11092178/S1.
- Pagdepanichkit S, Tribuddharat C, Chuanchuen R (2016). Distribution and expression of the Ade multidrug efflux systems in *Acinetobacter baumannii* clinical isolates. *CJM*, 62(9):794–801. doi:10.1139/CJM-2015-0730.
- Pandey N, Cascella M (2022). Beta-Lactam Antibiotics. *ADD*, 9781461414001:79–117. doi:10.1007/978-1-4614-1400-1\_3.
- Papich MG (2016). Ertapenem. *Saunders Handbook of Veterinary Drugs*. Elsevier; 2016:296–297. doi:10.1016/B978-0-323-24485-5.00246-1.
- Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (2011). Carbapenems: Past, present, and future. *AAC*, 55(11):4943–4960.
- Pincus DH. *Microbial Identification Using The Biomerieux® 2 System*. ([www.pda.org/bookstore](http://www.pda.org/bookstore)).
- Pourhajibagher M, Hashemi FB, Pourakbari B, Aziemzadeh M, Bahador A (2016). Antimicrobial Resistance of *Acinetobacter baumannii* to Imipenem in Iran: A Systematic Review and Meta-Analysis. *OMJ*, 10(1):32–42.
- Prasai A, Pant A, Neupane A, Pant S, Pradhan S (2021). Extensive drug resistant *acinetobacter* species isolates in sputum sample of patient admitted in intensive care unit of a tertiary care centre: A descriptive cross-sectional study. *Journal of the Nepal Medical Association*, 59(242):996–969.



- Prihatini, Aryati, Hetty (2007). Identifikasi Cepat Mikroorganisme Menggunakan Alat Vitek 2. PKILM, 13(3):129–32.
- Primasari FS, Puspitasari I, Nuryastuti T (2022). Prevalensi Bakteri Resisten Karbapenem di RSUP Dr. Sardjito Periode Januari-Agustus 2020. Majalah Farmaseutik, 18(3):265.
- Protic D, Pejovic A, Andjelkovic D, Djukanovic N, Savic D, Piperac P *et al.* (2016). Nosocomial infections caused by *acinetobacter baumannii*: Are we losing the battle? SUR, 17(2):236–242.
- Ramette A, Kronenberg A, Burnens A, Cherkaoui A, Dubuis O, Egli A *et al.* (2018). Prevalence of carbapenem-resistant *Acinetobacter baumannii* from 2005 to 2016 in Switzerland. BMC Infect Dis, 18(1).
- Said D, Willrich N, Ayobami O, Noll I, Eckmanns T, Markwart R (2021). The epidemiology of carbapenem resistance in *Acinetobacter baumannii* complex in Germany (2014–2018): an analysis of data from the national Antimicrobial Resistance Surveillance system. ARIC, 10(1).
- Sato Y, Unno Y, Kawakami S, Ubagai T, Ono Y (2017). Virulence characteristics of *Acinetobacter baumannii* clinical isolates vary with the expression levels of omps. JMM, 66(2):203–204.
- Sebeny PJ, Riddle MS, Petersen K (2008). *Acinetobacter baumannii* skin and soft-tissue infection associated with war trauma. CID, 47(4):444–449.
- Siegel JD, Rhinehart E, Jackson M, Linda ; (2007). Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006. AJIC, (35). doi:10.1016/j.ajic.2007.10.006.
- Singh H, Thangaraj P, Chakrabarti A (2013). *Acinetobacter baumannii*: A brief account of mechanisms of multidrug resistance and current and future therapeutic management. JCDR, 7(11):2602–2605.
- Tal-Jasper R, Katz DE, Amrami N, Ravid D, Avivi D, Zaidenstein R *et al.* (2016). Clinical and epidemiological significance of carbapenem resistance in *Acinetobacter baumannii* infections. AAC, 60(5):3127–3131.
- Ulu-Kiliç A, Ergönül Ö, Kocagül-Çelikbaş A, Dokuzoğuz B (2011). *Acinetobacter baumannii* bakteriyemilerinde mortalite için risk faktörleri. KD, 24(3):162–166.
- Uppalapati SR, Sett A, Pathania R (2020a). The Outer Membrane Proteins OmpA, CarO, and OprD of *Acinetobacter baumannii* Confer a Two-Pronged Defense in Facilitating Its Success as a Potent Human Pathogen. Front Microbiol, 11:2–5.
- Wang SH, Yang KY, Sheu CC, Chen WC, Chan MC, Feng JY *et al.* (2022). The necessity of a loading dose when prescribing intravenous colistin in critically ill patients with CRGNB-associated pneumonia: a multi-center observational study. Crit Care, 26(1):91. doi:10.1186/S13054-022-03947-9.
- Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H (1999). Nosocomial Bloodstream Infections Caused by *Acinetobacter* Species in United States Hospitals: Clinical Features, Molecular Epidemiology, and Antimicrobial Susceptibility. CID, 31:690–697. (<http://cid.oxfordjournals.org/>).
- Yapson GYA, Sukrama IDM, Budayanti NNS, Hendrayana MA (2023). Pola Kepekaan Bakteri *Acinetobacter baumannii* terhadap beberapa antibiotik pada pasien rawat inap di RSUP Dr. I.G.N.G Ngoerah Denpasar Tahun 2021. MU, 12(7):37–44.



UNIVERSITAS  
GADJAH MADA

- Zhang Y, Fan B, Luo Y, Tao Z, Nie Y, Wang Y *et al.* (2021). Comparative analysis of carbapenemases, RND family efflux pumps and biofilm formation potential among *Acinetobacter baumannii* strains with different carbapenem susceptibility. *BMC Infect Dis*, 21(1).
- Zuchrullah M, Nurdin E (2024). Deteksi Gen Resistensi Karbapenemase Dan Metallo-B-Lactamase Pada *Acinetobacter Baumannii*. *JMAK*, 15(1):25–34.